Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT ID: NCT00150293
Last Updated: 2015-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
337 participants
INTERVENTIONAL
2002-03-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
NCT00141388
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT00143143
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00141336
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
NCT00141245
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
NCT00141414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cannot be receiving any concomitant medication that could alter the effectiveness of the pregabalin response or affect seizure frequency.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Deakin, Australian Capital Territory, Australia
Pfizer Investigational Site
Camperdown, New South Wales, Australia
Pfizer Investigational Site
Chastwood, New South Wales, Australia
Pfizer Investigational Site
Cairns, Queensland, Australia
Pfizer Investigational Site
Maroochydore, Queensland, Australia
Pfizer Investigational Site
Footscray, Victoria, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Auenbruggerplatz 22, , Austria
Pfizer Investigational Site
Graz, , Austria
Pfizer Investigational Site
Innsbruck, , Austria
Pfizer Investigational Site
Linz, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Penticton, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Barrie, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Windsor, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Regina, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Ulm, Baden-Wurttemberg, Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bernau, , Germany
Pfizer Investigational Site
Bonn, , Germany
Pfizer Investigational Site
Dresden, , Germany
Pfizer Investigational Site
Erlangen, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
AE Breda, , Netherlands
Pfizer Investigational Site
Blaricum, , Netherlands
Pfizer Investigational Site
Ve Heeze, , Netherlands
Pfizer Investigational Site
Bialystok, , Poland
Pfizer Investigational Site
Bydgoszcz, , Poland
Pfizer Investigational Site
Choroszcz, , Poland
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Gdansk, , Poland
Pfizer Investigational Site
Grudziądz, , Poland
Pfizer Investigational Site
Katowice, , Poland
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Lublin, , Poland
Pfizer Investigational Site
Mosina, , Poland
Pfizer Investigational Site
Olsztyn, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Płock, , Poland
Pfizer Investigational Site
Torun, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Granada, Granada, Spain
Pfizer Investigational Site
Málaga, Malaga, Spain
Pfizer Investigational Site
Zaragoza, Zaragoza, Spain
Pfizer Investigational Site
Girona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Middlesbrough, N. York, United Kingdom
Pfizer Investigational Site
Washington, Tyne & Wear, United Kingdom
Pfizer Investigational Site
Blackpool, , United Kingdom
Pfizer Investigational Site
Dundee, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Northampton, , United Kingdom
Pfizer Investigational Site
Wolverhampton, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008-114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.